FENNEC PHARMACEUTICALS INC.
For the period ended Dec 31, 2025. Filed Mar 27, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 27, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 9B. Other Information
Insider Adoption or Termination of Trading Arrangements
During the year ended December 31, 2025, two members of our Board of Directors adopted trading arrangements intended to satisfy the Rule 10b5-1 affirmative defense. Rostislav Raykov adopted a trading arrangement on September 19, 2025, covering the disposition of up to 109,184 shares of the Company’s common shares, which is scheduled toterminate on June 9, 2026. Chris Rallis adopted a trading arrangement on May 19, 2025, covering the disposition of up to 18,406 shares of the Company’s common shares, which will terminate on June 9, 2026, unless earlier terminated in accordance with its terms.
No additional directors or officers informed us of the adoption, modification or termination of a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as those terms are defined in Regulation S-K, Item 408.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.